mathom/ct_dataset huggingface dataset:
Trial Id: Breast Cancer Index (BCI) Registry Recruitment Status: Active, not recruiting Trail description: The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy. Inclusion Criteria: Early stage (I, II or III) female breast cancer patients, who have completed 4-7 years of primary adjuvant endocrine therapy
Patient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed ductal/lobular).
The primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive and/or progesterone receptor-positive.
The primary tumor was HER2 negative or positive and node-negative or node-positive with 1-3 positive lymph nodes.
Subject has pre-treatment breast tumor tissue [formalin fixed and paraffin embedded (FFPE)] from a previous breast-conserving surgery, mastectomy or core needle biopsy available for testing by the Sponsor. Exclusion Criteria: Patient has distant metastatic disease (M1).
Patient was diagnosed with metaplastic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, or phyllodes tumor.
Provide inclusion criteria for trial id: NCT04875351  
 Early stage (I, II or III) female breast cancer patients, who have completed 4-7 years of primary adjuvant endocrine therapy
Patient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed ductal/lobular).
The primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive and/or progesterone receptor-positive.
The primary tumor was HER2 negative or positive and node-negative or node-positive with 1-3 positive lymph nodes.
Subject has pre-treatment breast tumor tissue [formalin fixed and paraffin embedded (FFPE)] from a previous breast-conserving surgery, mastectomy or core needle biopsy available for testing by the Sponsor.
Trial Id: Breast Cancer Risk Assessment in Women Aged 40-49 Recruitment Status: Completed Trail description: In a randomized controlled trial, the investigators will test the effect of a novel strategy for breast cancer risk assessment and risk-based management of women in their 40s seen in primary care. The investigators anticipate that this approach will lead to more optimal use of mammography screening and breast cancer prevention interventions in women in their 40s and as a result will improve care of these women. Inclusion Criteria: women
aged 40-49 years
read and speak English
scheduled for a routine visit or physical examination with a non-resident PCP in the next 4-12 weeks at HealthCare Associates (HCA, BIDMC's outpatient primary care practice). Exclusion Criteria: women scheduled for acute care
women who had or will have a mammogram within 6 months of their PCP visit
women with a history of breast cancer or a BRCA mutation
women already receiving screening breast MRIs
women who have been referred to genetic counseling
women who have taken or are taking tamoxifen or aromatase inhibitors for breast cancer prevention
women with a history of an abnormal mammogram in the past two years
women with a history of breast enlargement or reduction.
Provide exclusion criteria for trial id: NCT03180086  
 women scheduled for acute care
women who had or will have a mammogram within 6 months of their PCP visit
women with a history of breast cancer or a BRCA mutation
women already receiving screening breast MRIs
women who have been referred to genetic counseling
women who have taken or are taking tamoxifen or aromatase inhibitors for breast cancer prevention
women with a history of an abnormal mammogram in the past two years
women with a history of breast enlargement or reduction.
Trial Id: Diagnosis Value of SEMA4C in Breast Cancer Recruitment Status: Not yet recruiting Trail description: Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C. Inclusion Criteria: Receiving no treatment before diagnosis
Establishing Diagnosis according to biopsy or surgery Exclusion Criteria: Patients who are not mentally capable of giving written informed consent
Clinical data missing
Serum samples doesn't qualified
Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results
Provide description for trial id: NCT03662633  
 Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C.
Trial Id: A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China Recruitment Status: Unknown status Trail description: The purpose of the study is to study the epidemic features and diagnosis of female breast cancer, especially the diagnosis and treatment of breast cancer.The disease-free survival (DFS) and the total survival time(OS) of the breast cancer patients will also be studied. Inclusion Criteria: Female patients;
The hospitalized patients who are confirmed of the primary breast cancer histologically;
The date of the inpatients are within the month we chosen;
Patients who are within the month we chosen have been received or under receiving the relevant treatment including surgical treatment, chemotherapy and radiotherapy. Exclusion Criteria: Male breast cancer patients;
Patients with breast cancer who are not under the chosen time;
Non hospitalized patients.
Trial Id: Role of Sorcin and Annexin A3 in Breast Cancer Patients Recruitment Status: Unknown status Trail description: Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality.

Reliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies. Inclusion Criteria: breast cancer patients before surgery who are admitted to the South Egypt Cancer Institute, Surgery Department, Assiut University Exclusion Criteria: • Patients with malignancies elsewhere in the body.

Patients with chronic cardiac diseases.
Getting neoadjuvant chemotherapy.
Renal disease.
Neurodegenerative disease.
Provide description for trial id: NCT03598660  
 Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality.

Reliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies.
Trial Id: Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases Recruitment Status: Recruiting Trail description: Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called "Skeletal-related Events" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at "high risk" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer. Inclusion Criteria: Adult women (≥ 18 years) candidates for excisional surgery and bone consolidation due to osteolytic bone metastases from breast cancer.
Female
Ability to understand the experimental study and willingness to sign the written consent Exclusion Criteria: - Retraction of written consent
Provide description for trial id: NCT04167605  
 Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called "Skeletal-related Events" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at "high risk" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer.
Trial Id: Can MicroRNA's Predict Multicentricity in Breast Cancer? Recruitment Status: Completed Trail description: The aim of this study is to determine if microRNA's have role in predicting multicentricity in breast cancer. If a specific microRNA will be found to be related with multicentricity, it will help us to make appropriate decisions on the treatment of patients with multicentric breast cancer. Inclusion Criteria: Having breast cancer
Having no other malignancy
Female patient Exclusion Criteria: Having other malignancy
Under 18 years old
Male patient
Trial Id: A Study to Identify Breast Cancer (IDBC) Recruitment Status: Unknown status Trail description: Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.

The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics. Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT04495244  
 Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.

The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.
Trial Id: The Effect of Breast Cancer Prevention Journey Program Recruitment Status: Not yet recruiting Trail description: The aim of this quasi-experimental study is to determine the effect of the "Breast Cancer Prevention Journey Program" on health beliefs about breast cancer in women over 40 years of age who have never had a mammogram before. The research aims to answer the following basic questions:

-Do women who participated in the "Breast Cancer Prevention Journey Program" have different health beliefs about breast cancer than women who did not participate in the program? The researchers will compare the program with routine care to see if the "Breast Cancer Prevention Journey Program" works. The study will be conducted in a quasi-experimental design with a pre-test post-test control group.

Participants in the experimental group will first participate in the "The fight against breast cancer" training structured according to the Health Belief Model. One week after the training, the participants in the experimental group will be taken to mammography screening with free shuttles.

Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Inclusion Criteria: Being a woman between the ages of 40-69
Having never had a mammogram before Exclusion Criteria: Being diagnosed with breast cancer
Having had a breast operation
Provide description for trial id: NCT06395896  
 The aim of this quasi-experimental study is to determine the effect of the "Breast Cancer Prevention Journey Program" on health beliefs about breast cancer in women over 40 years of age who have never had a mammogram before. The research aims to answer the following basic questions:

-Do women who participated in the "Breast Cancer Prevention Journey Program" have different health beliefs about breast cancer than women who did not participate in the program? The researchers will compare the program with routine care to see if the "Breast Cancer Prevention Journey Program" works. The study will be conducted in a quasi-experimental design with a pre-test post-test control group.

Participants in the experimental group will first participate in the "The fight against breast cancer" training structured according to the Health Belief Model. One week after the training, the participants in the experimental group will be taken to mammography screening with free shuttles.

Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health.
Trial Id: Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay Recruitment Status: Unknown status Trail description: Blood samples from a total of 200 women in two cohorts will be collected and analyzed by TM-B1 assay, which is based on TBIA (Total Biochemical Infrared Analysis) to confirm the presence of cancer. These two cohorts will yield 75 healthy women with no pathological findings, 75 women diagnosed as having benign breast tumor and 50 women diagnosed as having breast cancer. Inclusion Criteria: Screening Population:

Subject signed the informed consent.
Subject is aged 25 years and older.
Subject is presenting for routine screening or diagnostic XRM and / or breast US.

Breast Cancer Population

Subject signed the informed consent form.
Subject is aged 25 years and older.
Subject was diagnosed with a malignant breast tumor, and has not yet started treatment. Exclusion Criteria: All Subjects:

Subject has been diagnosed with any type of malignancy apart from breast cancer.
Subject has been previously treated for breast cancer.
Subject underwent any surgery within the previous year (apart from benign nevus removal).
Subject was treated for benign tumor within the previous year (e.g. polyps or cysts).
Subject has an active infection or inflammation from any type of infection (bacterial or viral) as determined clinically at screening.
Subject is currently taking medications related directly to, or that can affect, the immune system such as steroids.
Subject has any type of active autoimmune disease such as lupus or rheumatoid arthritis.
Diagnostic drugs (e.g. contrast materials) were injected or given orally to subject within the last 7 days prior to sample collection for TM-B1 analysis.
Subject has been taking any investigational drug which influence her health status within 30 days prior to sample collection for TM-B1 analysis.
Subject is not feeling well at the time of blood collection for TM-B1 analysis due to suspected bacterial or viral infection or subject has symptoms such as high fever, diarrhea, headache, vomiting, dizziness etc.
Subject is pregnant, lactating, or undergoing fertility treatment.
Subject has participated in this study, in another cohort, and the TM-B1 test was performed.

Breast Cancer Population only:

The subject's tumor has been surgically removed before sample collection for TM-B1 analysis.
Provide exclusion criteria for trial id: NCT03343691  
 All Subjects:

Subject has been diagnosed with any type of malignancy apart from breast cancer.
Subject has been previously treated for breast cancer.
Subject underwent any surgery within the previous year (apart from benign nevus removal).
Subject was treated for benign tumor within the previous year (e.g. polyps or cysts).
Subject has an active infection or inflammation from any type of infection (bacterial or viral) as determined clinically at screening.
Subject is currently taking medications related directly to, or that can affect, the immune system such as steroids.
Subject has any type of active autoimmune disease such as lupus or rheumatoid arthritis.
Diagnostic drugs (e.g. contrast materials) were injected or given orally to subject within the last 7 days prior to sample collection for TM-B1 analysis.
Subject has been taking any investigational drug which influence her health status within 30 days prior to sample collection for TM-B1 analysis.
Subject is not feeling well at the time of blood collection for TM-B1 analysis due to suspected bacterial or viral infection or subject has symptoms such as high fever, diarrhea, headache, vomiting, dizziness etc.
Subject is pregnant, lactating, or undergoing fertility treatment.
Subject has participated in this study, in another cohort, and the TM-B1 test was performed.

Breast Cancer Population only:

The subject's tumor has been surgically removed before sample collection for TM-B1 analysis.
Provide description for trial id: NCT03343691  
 Blood samples from a total of 200 women in two cohorts will be collected and analyzed by TM-B1 assay, which is based on TBIA (Total Biochemical Infrared Analysis) to confirm the presence of cancer. These two cohorts will yield 75 healthy women with no pathological findings, 75 women diagnosed as having benign breast tumor and 50 women diagnosed as having breast cancer.
Trial Id: FH-Risk 2.0: Updating Breast Cancer Risk Estimates Recruitment Status: Completed Trail description: In the UK women with a strong family history of breast cancer are eligible for breast cancer risk estimation via Family History Risk and Prevention Clinics (FHRPCs). Here breast cancer risk is calculated using popular risk prediction models like the Tyrer-Cuzick, CanRisk or Gail models. These models combine breast cancer risk factors to calculate a risk estimate for women. Risk factors include, family history, hormonal and reproductive factors, and risk factors related to health behaviours, for example, smoking, exercise and alcohol intake.

Recently, risk estimation for breast cancer has become more accurate with the inclusion of mammographic density and Single Nucleotide Polymorphisms (SNPs) into popular risk prediction models. The addition of these new risk factors could alter the risk estimates that women in FHRPCs have been provided. How much these new risk factors alter a previously given risk estimate is unknown. It is also unknown how women will react to a revised risk estimate, especially if it changes their previous estimate and their access to preventive management options.

This research aims to explore this gap in the literature. Inclusion Criteria: previously given informed consent to participate in the original FH-Risk study,
have an up to date clear mammogram,
aged between 25 and 60,
have not developed breast cancer and,
have the capacity to consent. Exclusion Criteria: women who have received a diagnosis of breast cancer,
women who have not had a clear mammogram,
women who took part in the original FH-Risk study but did not consent for their data to be used in future research and,
women who lack the capacity to consent.
Provide description for trial id: NCT05082740  
 In the UK women with a strong family history of breast cancer are eligible for breast cancer risk estimation via Family History Risk and Prevention Clinics (FHRPCs). Here breast cancer risk is calculated using popular risk prediction models like the Tyrer-Cuzick, CanRisk or Gail models. These models combine breast cancer risk factors to calculate a risk estimate for women. Risk factors include, family history, hormonal and reproductive factors, and risk factors related to health behaviours, for example, smoking, exercise and alcohol intake.

Recently, risk estimation for breast cancer has become more accurate with the inclusion of mammographic density and Single Nucleotide Polymorphisms (SNPs) into popular risk prediction models. The addition of these new risk factors could alter the risk estimates that women in FHRPCs have been provided. How much these new risk factors alter a previously given risk estimate is unknown. It is also unknown how women will react to a revised risk estimate, especially if it changes their previous estimate and their access to preventive management options.

This research aims to explore this gap in the literature.